Research Reports in Clinical Cardiology (Feb 2013)

Galectin-3: clinical utility and prognostic value in patients with heart failure

  • Kramer F

Journal volume & issue
Vol. 2013, no. default
pp. 13 – 22

Abstract

Read online

Frank KramerClinical Sciences, Global Biomarker Strategy and Development, Bayer HealthCare, Wuppertal, GermanyAbstract: This review summarizes the key findings of 14 clinical trials in which Galectin-3 was assessed as a biomarker of heart failure. In addition, most relevant information available about Galectin-3 biology generated in in vitro and in vivo research is discussed in the context of heart failure.Keywords: biomarker, cardiovascular disease, therapy monitoring, prediction of outcome, patient stratification